Syndax Pharmaceuticals Inc. announced Revuforj was added to NCCN Guidelines for AML. Revumenib received Category 2A recommendation for R/R AML with mNPM1 mutation. FDA is reviewing sNDA for approval, with PDUFA target action date of October 25. Syndax is a biopharmaceutical company focusing on cancer treatments. Stock offers potential, but other AI stocks may have greater upside.

Read more at Yahoo Finance: Syndax’s Revumenib Added to NCCN AML Guidelines Ahead of October 25 FDA Decision